The Clinical Effects Of Metformin And Acarbose On Diabetic Peripheral Arterial Disease

Object : The number of patients with diabetes mellitus is rapidly increasing, and the chronic complications of diabetes mellitus has become a serious major infectious diseases threat to human health. Diabetes can cause multiple organ damage, and heart cerebral vascular disease caused by diabetes are the main reasons of death, and cerebral vascular disease and peripheral vascular disease(PAD), has seriously affected the quality of life of the patients. In diabetic vascular sclerosis of arterial congee appearance the prevention and treatment of complications and become the key for the treatment of diabetic complications. Diabetic lower extremity vascular lesions(LEAD), for diabetic peripheral vascular disease(Diabetes- PAD) is an important part of, is one of the common severe chronic complications of Diabetes, the Diabetes vascular lesions of judgment, to Ankle brachial index(ABI) as a recognized indicators. Treated the first diagnosis in patients with T2 DM with metfoimin and acarbose respectively and observed the changes of ABI in Hb A1C≤7%. Observed if the hypoglycemic therapy can influence the process of diabetic PAD and whether there is a difference between two drugs’ effect on T2 DM. To investigate the two drugs whether there were protection effects on peripheral vascular.Methods: This study intents to include about 100 the first diagnosis patients with the T2 DM and divided randomly into 2 groups, oral metformin and acarbose respectively and follow up 3,6,9 and 12 months. Observed the ABI whether there were statistically difference between the two groups in Hb A1C≤7%, blood pressure, blood lipid control under the condition of same baseline indicators and investigated two drugs there were vascular protection effects. To contrast between groups ABI before and after the treatment, in the case of strict control Hb A1C≤7%, observed whether strengthening hypoglycemic can improve the prognosis of diabetic vascular lesions.Results: Analyzed the glycometabolism and ABI results of two groups that patients who oral metformin and acarbose respectively. The metformin groups of patients’ blood sugar, glycosylated hemoglobin, blood lipid(total cholesterol), and blood pressure were decreased and have statistical significance(P<0.05) than before treatment. The acarbose group of patients’ blood sugar, glycosylated hemoglobin, blood lipid(total cholesterol), significantly lower than before treatment and have statistical significance(P < 0.05). The effect of metformin on lowering blood sugar, reduce glycated hemoglobin is better than that of acarbose(P<0.05), and has a unique of lowering blood pressure. The role of the two drugs can increase ABI(both P<0.05), reduce the incidence rate of PAD and the effect of metformin is better than acarbose(P<0. 05).Conclusion:Both of Metformin and acarbose can reduce blood sugar, glycosylated hemoglobin, blood lipid(total cholesterol), so as to increase the effect of ABI and reduce the incidence rate of PAD. Metformin is better than acarbose in terms of reduce blood sugar, glycosylated hemoglobin, blood pressure and increase ABI.